Dose variability has long been one of the central challenges in inhaled cannabinoid therapy. In a new clinical article, Dr Simon Erridge, Research Director at Curaleaf Clinic UK, examines how standardised inhalation technology may support more consistent, reproducible cannabinoid delivery — and what this means for dose titration in clinical practice.
The article looks at the QMID (Que Medical Inhalation Device), a standardised inhalation platform built around a controlled inhalation cycle, paired with cartridges that have undergone analytical testing to quantify cannabinoid delivery per puff.
Dr Erridge discusses how this level of dose predictability may support more structured titration approaches, particularly for cannabis-naïve or clinically sensitive patients, and reviews early real-world evidence from the UK Medical Cannabis Registry on patient-reported outcomes and safety.
Dr Simon Erridge, Precision Inhalation in Medical Cannabis: Dose Consistency and Clinical Considerations for Inhaled Cannabinoid Therapy
